Advertisement

Sodium Diethyldithiocarbamate (Imuthiol) and Cancer

  • G. Renoux
  • M. Renoux
  • E. Lemarie
  • M. Lavandier
  • J. Greco
  • P. Bardos
  • J. M. Lang
  • A. Boilletot
  • F. Oberling
  • J. Armand
  • A. Mussett
  • G. Biron
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 166)

Abstract

Immune impairment or dysfunction is associated with cancers, and is frequently aggravated by conventional therapies. As a consequence, the development of agents active on the immune system in ways that restore or regulate host defenses, has become a major objective. An overall appreciation of the published data led us to conceptualize the following requirements for suitable immunopharmacologic agents. Absence of carcinogenicity, of tumor promoting influence and of antigenicity or sensitizing effects, is an essential prerequisite since these agents will be administered for long periods of time to patients already at risk. They should have defined influences on populations or subpopulations of immunocompetent cells, as their essential activities. Their toxic levels and pharmacologic effects should be known to delineate the range of doses and predict most side effects. Such requirements will reasonably eliminate most of the inconsistencies which have somewhat dampened confidence in therapies intended to modify the immune system.

Keywords

Lung Cancer Patient Athymic Mouse Cell Mitogen Spindle Cell Carcinoma Lymphoproliferative Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Renoux, G., and M. Renoux. 1974. C. R. Acad. Sci. (Paris) 278 D: 1139.Google Scholar
  2. 2.
    Renoux, G. 1980. Drugs 20: 89.PubMedCrossRefGoogle Scholar
  3. 3.
    Blacow, N. W. 1972. Martindale the Extra Pharmacopoeia, 26th Edition. The Pharmaceutical Press, London.Google Scholar
  4. 4.
    Renoux, G. 1982. J. Pharmacol. (Paris) 13 (in press).Google Scholar
  5. 5.
    Borch, R. F. and M. E. Pleasant. 1979. Proc. Natl. Acad. Sci. USA 76: 6611.CrossRefGoogle Scholar
  6. 6.
    Borch, R. F., J. C. Katz, P. H. Lieder, and M. E. Pleasant. 1980. Proc. Natl. Acad. Sci. USA 77: 5441.CrossRefGoogle Scholar
  7. 7.
    Gale, G. R., and L. M. Atkins. 1981. J. Clin. Hematol. Oncol. 11: 41.Google Scholar
  8. 8.
    Lin, P. S., L. Kwock, and N. T. Goodchild. 1980. Cancer 46: 2360.PubMedCrossRefGoogle Scholar
  9. 9.
    Powell, A. K. 1954. Brit. J. Cancer 8: 529.PubMedCrossRefGoogle Scholar
  10. 10.
    Blagoeva, P. and I. Stoichev. 1979. Experientia 35: 1389.PubMedCrossRefGoogle Scholar
  11. 11.
    National Cancer Institute. 1979. Technical Rep. Series 172Google Scholar
  12. 12.
    Renoux, G., and M. Renoux. 1979. J. Immunopharmacol. 1: 247.PubMedGoogle Scholar
  13. 13.
    Renoux, G. 1980. In B. Serrou and C. Rosenfeld (eds.), New trends in human immunology and cancer immunotherapy. Doin, Paris.Google Scholar
  14. 14.
    Renoux, G. and M. Renoux. 1981. In E. M. Hersh, M. A. Chirigos, and M. Mastrangelo (eds.), Augmenting agents in cancer therapy. Raven Press, New York.Google Scholar
  15. 15.
    Renoux, G. and M. Renoux. 1982. In B. Serrou et al. (eds.), Current concepts in human immunology and cancer immunomodulation. Elsevier Biomedical Press, Amsterdam.Google Scholar
  16. 16.
    Neveu, P. J. 1978. Clin. Exp. Immunol. 32: 419.PubMedGoogle Scholar
  17. 17.
    Renoux, G., P. Bardos, D. Degenne, M. Musset. In R. B. Herberman (ed.), Natural cell-mediated immunity. Academic Press, New York (in press).Google Scholar
  18. 18.
    Renoux, G. and M. Renoux. 1980. Clin. Immunol. Immunopathol. 15: 21.CrossRefGoogle Scholar
  19. 19.
    Renoux, G. 1982. In M. Rola-Pleszczynski, P. Sirois (eds.). Immunopharmacology. Elsevier/North-Holland.Google Scholar
  20. 20.
    Scherwin, St. 1982. In G. Mathé et al (eds.) Tumor Pharmacology, Paris.Google Scholar
  21. 21.
    Renoux, G. and M. Renoux. 1977. J. Exp. Med. 145: 466.PubMedCrossRefGoogle Scholar
  22. 22.
    Renoux, G., M. Renoux, J. M. Guiolaumin, and C. Gouzien. 1979. J. IMmunopharmacol. 1: 145.Google Scholar
  23. 23.
    Renoux, G. and M. Renoux. 1980. Thymus 2: 139.PubMedGoogle Scholar
  24. 24.
    Renoux, G., J. L. Touraine, and M. Renoux. 1980. J. Immuno-pharmacol. 2: 49.CrossRefGoogle Scholar
  25. 25.
    Renoux, G., K. Bizière, M. Renoux and J. M. Guillaumin. 1980. C. R. Acad. Sci. (Paris) 290 D: 719.Google Scholar
  26. 26.
    Bardos, P., D. Degenne, Y. Lebranchu, K. Bizière, and G. Renoux. 1981. Scand. J. Immunol. 13: 609.PubMedCrossRefGoogle Scholar
  27. 27.
    Bizière, K., G. Renoux, and M. Renoux. 1982. Neuroscience 7: 528.Google Scholar
  28. 28.
    Renoux, G., K. Bizière, and M. Renoux. 1982. Bull. Acad. Nat. Med. 166: 88.Google Scholar
  29. 29.
    Renoux, G., K. Bizière, M. Renoux, and J. M. Guillaumin. 1982. Scand. J. Immunol. (in press).Google Scholar
  30. 30.
    Renoux, G., K. Bizière, P. Bardos, D. Degenne, and M. Renoux. 1982. In R. B. Herberman (ed.), Natural cell-mediated immunity. Academic Press, New York (in press).Google Scholar
  31. 31.
    Hewlett, G., H-G. Opitz, and H. D. Schlumberger. 1981. In E. Pick and M. Landy (eds.) Lymphokines, Vol. 4. Academic Press, New York.Google Scholar
  32. 32.
    Renoux, G., M. Renoux, J. Greco, J. Baudouin, M. Lavandier, and E. Lemarié. 1980. In B. Serrou and C. Rosenfeld (eds.), New trends in human immunology and cancer immunotherapy. Doin, Paris.Google Scholar
  33. 33.
    Prabhakaran, K., E. B. Harris, and W. F. Kirchheimer. 1972. Microbios. 5: 273.PubMedGoogle Scholar
  34. 34.
    Renoux, G. 1979. Internatl. J. Immunopharmacol. 1: 43CrossRefGoogle Scholar
  35. 35.
    Renoux, G., and M. Renoux. 1982. In R. L. Fenichel (ed.), Immunomodulating agents. Marcel Dekker, New York (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • G. Renoux
    • 1
  • M. Renoux
    • 1
  • E. Lemarie
    • 2
  • M. Lavandier
    • 2
  • J. Greco
    • 3
  • P. Bardos
    • 1
  • J. M. Lang
    • 4
  • A. Boilletot
    • 4
  • F. Oberling
    • 4
  • J. Armand
    • 5
  • A. Mussett
    • 5
  • G. Biron
    • 5
  1. 1.Laboratoire d’ImmunologieCHU Bretonneau-TrousseauToursFrance
  2. 2.Service de PneumologieCHU Bretonneau-TrousseauToursFrance
  3. 3.Service de Chirurgie BCHU Bretonneau-TrousseauToursFrance
  4. 4.Service des Maladies du SangCHU d’HautepierreStrasbourgFrance
  5. 5.Institut MérieuxFrance

Personalised recommendations